| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $577,300 | 1 | 14 |
Sells | $148,445 | 6 | 86 |
| Hagler Mark Arnold | See Remarks | 1 | $577,300 | 0 | $0 | $577,300 |
| Dennis Phillip Andrew | Chief Medical Officer | 0 | $0 | 1 | $5,606 | $-5,606 |
| Xu Cong Claire | SVP, Clinical Development | 0 | $0 | 3 | $20,351 | $-20,351 |
| Cao Sean Wuxiong | See Remarks | 0 | $0 | 2 | $122,488 | $-122,488 |
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International …
Over the last 12 months, insiders at NovaBridge Biosciences have bought $577,300 and sold $148,445 worth of NovaBridge Biosciences stock.
On average, over the past 5 years, insiders at NovaBridge Biosciences have bought $577,300 and sold $148,445 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hagler Mark Arnold (See Remarks) — $577,300.
The last purchase of 230,000 shares for transaction amount of $577,300 was made by Hagler Mark Arnold (See Remarks) on 2026‑04‑24.
| 2026-09-09 | Sale | Cao Sean Wuxiong | Chief Bus. Development Officer | 107,978 0.0408% | $0.74 | $79,904 | -19.41% | |
| 2026-08-31 | Sale | Xu Cong Claire | EVP, Clinical Development | 3,282 0.0028% | $0.79 | $2,593 | -24.73% | |
| 2026-07-06 | Sale | Xu Cong Claire | SVP, Clinical Development | 4,485 0.0017% | $0.89 | $3,992 | -18.41% | |
| 2026-06-18 | Sale | Dennis Phillip Andrew | Chief Medical Officer | 8,494 0.0032% | $0.66 | $5,606 | +9.33% | |
| 2026-06-01 | Sale | Xu Cong Claire | SVP, Clinical Development | 3,494 0.007% | $3.94 | $13,766 | -4.39% | |
| 2026-05-14 | Sale | Cao Sean Wuxiong | See Remarks | 21,399 0.0192% | $1.99 | $42,584 | -12.50% | |
| 2026-04-24 | Hagler Mark Arnold | See Remarks | 230,000 0.2044% | $2.51 | $577,300 | -29.39% |
| Increased Positions | 38 | +90.48% | 9M | +31.89% |
| Decreased Positions | 17 | -40.48% | 5M | -15.98% |
| New Positions | 22 | New | 2M | New |
| Sold Out Positions | 5 | Sold Out | 358,224 | Sold Out |
| Total Postitions | 63 | +50% | 34M | +15.91% |